FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Moderna's Great Immunological Blunder
Copy link
Facebook
Email
Notes
More

Moderna's Great Immunological Blunder

Failure to Recognize Potential for Auto-Immune Disorders with Prophylactic Vaccines

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Feb 23, 2024
∙ Paid
160

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Moderna's Great Immunological Blunder
Copy link
Facebook
Email
Notes
More
43
15
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

Many have asked me how Moderna, a dedicated mRNA company, could make such a bad product out of the gate as their first market entry? Much of the answer relates to a development blunder made by Moderna scientists dating back many years.

Because mRNA rapid design and implementation is so enthralling, companies like Moderna began to imagine any disease that could be modulated by harnessing human cells to produce a protein of interest. In their 2018 Securities and Exchange Commission 10-K filing there is a figure that caught my attention. Moving right to left one can see the thought process of young molecular biologists with dreams of treating broad range of diseases.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More